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Little is known about effects of community-based physiotherapeutic exercise programmes
incorporated in COPD self-management programmes. In a randomised trial, the effect of such
a programme (COPE-active) on exercise capacity and various secondary outcomes including
daily activity as a marker of behaviour change was evaluated.
All patients attended four 2-h self-management sessions. In addition the intervention group
participated in the COPE-active programme offered by physiotherapists of private practices,
consisting of a 6-month “compulsory” period (3 sessions/week) and subsequently a 5-month
“optional” period (2 sessions/week). Because COPE-active was intended to change behaviour
with regard to exercise, one session/week in both periods consisted of unsupervised home-
based exercise training.
Of 153patients, 74 interventionand68control patients completed theone-year follow-up. Statis-
tically significant between-group differences in incremental shuttlewalk test-distance (35.1m; 95%
CI (8.4; 61.8)) and daily activity (1190 steps/day; 95% CI (256; 2125)) were found in favour of the
intervention group. Over the 12-month period a significant difference of the chronic respiratory
questionnaire (CRQ) dyspnoea-score (0.33 points; 95% CI (0.01; 0.64)) and a non-significant differ-
ence of the endurance shuttle walk test (135 m (95% CI (29; 298)) was found. No differences were
found in theother CRQ-components, anxiety and depression scores andpercentageof fat freemass.n General Hospital, Department of Respiratory Medicine, Daws Road, Daw Park SA 5041, Australia.
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Community based physiotherapeutic exercise in COPD 419This study demonstrates that a community-based reactivation programme improves exercise
capacity in patients with moderately to severe COPD. Even more important, the programme
improves actual daily activity after one-year which indicates behaviour change with regard to daily
exercise.
Registered trail number: ISRCTN81447311
ª 2010 Elsevier Ltd. All rights reserved.Introduction
The natural course of COPD includes a progressive decline
in functional capacity and health-related quality of life
(HRQoL)1 and imposes a significant burden in terms of
disability2 and of costs.3 Therefore, optimisation of treat-
ment is an important goal. Treatment currently consists of
pharmacological interventions complemented by hospital-
based pulmonary rehabilitation, oxygen therapy in the
more severe patients, and attempts at life-style interven-
tions. Self-management programmes directed towards
behaviour change are recommended in COPD patients,4 but
there is still lack of clarity about the appropriate content
and effects of the various components of self-management
programmes.
Firm evidence exists for multi-disciplinary rehabilitation
programmes,5 however less is known about physiotherapeutic
exercise programmes as an extension of self-management
programmes. Studies reported divergent effects.4 A recent
study reported similar positive effects of an in-hospital and
a home-based exercise programmes in addition to a self-
management programme on quality of life and cycle endur-
ance time, but not on walking distance.6
Community-based physiotherapeutic exercise pro-
grammes, executed by local physiotherapists working in
private physiotherapy practices, are common in the
Netherlands. When proven effective, these programmes
would be a perfect extension to a self-management pro-
gramme because of their good accessibility. Nevertheless,
very few of these programmes have been evaluated in
randomised controlled trials and therefore this intervention
has not yet been demonstrated to be effective.7,8
Besides physical progress, physiotherapeutic exercise
programmes within self-management programmes should
aim on behavioural change towards exercise in daily life.
Therefore, we evaluated the effects of a community-based
physiotherapeutic exercise programme (COPE-active)
incorporated in a self-management programme, compared
to self-management only, on exercise capacity and daily
activity (as an indicator of behavioural change) using
a randomised controlled trial.Material and methods
Patients
From November 2004 to July 2006, 159 patients were
recruited from the outpatient pulmonary clinic of Medisch
Spectrum Twente hospital at Enschede, The Netherlands.
Patients had to meet the following criteria; (1) a clinical
diagnosis of COPD according to the GOLD criteria;1 (2) no
exacerbation in the month prior to enrolment; (3) 3exacerbations, defined as respiratory problems that
required a course of oral corticosteroids and/or antibiotics,
or one hospitalisation for respiratory problems in the two
years preceding study entry; (4) (ex) smoker; (5) age 40e75
years; (6) post-bronchodilator FEV1 25e80% of predicted;
(7) able to understand and read Dutch; and (8) written
informed consent from the subject prior to participation.
Patients were excluded if they had: (1) serious other
disease with a low survival rate; (2) other diseases influ-
encing bronchial symptoms and/or lung function (e.g.,
cardiac insufficiency, sarcoidosis); (3) severe psychiatric
illness; (4) uncontrolled diabetes mellitus during a COPD
exacerbation in the past or a hospitalisation for diabetes
mellitus in the two years preceding the study; (5) need for
regular oxygen therapy (>16 h/day or pO2<7.2 kPa); (6)
maintenance therapy with antibiotics; (7) known a1-anti-
trypsine deficiency; (8) disorders or progressive disease
seriously influencing walking ability (e.g., amputation,
paralysis, progressive muscle disease). The hospital’s
medical ethics committee approved the study.
Study design
A two-by-two factorial design was used, meaning that two
independent interventions (self-treatment of exacerba-
tions and a community-based physiotherapeutic exercise
programme) were evaluated using one design (Table 1).
This paper compares the effect of a self-management
programme including COPE-active (intervention group) with
a self-management programme only (control group).
Patients receiving guidelines for self-treatment of exacer-
bations were equally distributed over the intervention and
control group. This design assumes that both interventions
do not interact with each other which needs to be verified
before the final analyses. Patients were randomised into
two study groups, using a minimisation programme,9 mini-
mising differences between groups in gender, current
smoking, FEV1 predicted ( or >50%), use of inhaled
corticosteroid, and current participation in a regular
physiotherapy programme. In the first month self-manage-
ment sessions were offered to all patients, followed by the
start of the COPE-active programme in the intervention
group in the second month. During the whole study period,
patients in the control group were allowed to attend
regular, non-COPE-active physiotherapy sessions if this was
prescribed as part of regular care. Measurements were
performed at baseline, and after 7 and 12 months.
Self-management sessions
Smokers were offered a smoking cessation programme, the
Lung Minimal Intervention Strategy (LMIS),10 prior to the
group-allocation. Smoking cessation was attempted
Table 1 Description of the design of the COPE-II study, including the two interventions (self-treatment of exacerbations and
COPE-active) and the measurements at baseline, 7, and 12 months.
Time schedule Interventions Intervention group (ZCOPE-active
group) n Z 77
Control group n Z 76
Subgroup 1
(n Z 40)
Subgroup 2
(n Z 37)
Subgroup 3
(n Z 37)
Subgroup 4
(n Z 39)
Month 0 Baseline measurement X X X X
Month 1 Self-management sessions X X X X
Month 1e12 Self-treatment of
exacerbations
X e X e
Month 2e7 COPE-active: ‘compulsory’ X X e e
Month 7 Measurement X X X X
Month 8e12 COPE-active: ‘voluntary’ X X e e
Month 12 Measurement X X X X
420 T. Effing et al.individually (by a specialised nurse) during a 3-month
period. It included three individual sessions (one 60-min
intake and two 30-min sessions in week 2 and 3) and three
telephone contacts (at “quitting” day and in week 4 and
13). Pharmacological support was recommended during
LMIS counseling, but the use was voluntary and at the
patients’ costs.
After randomisation, all patients and their partners
(from both the intervention and control group) were
offered four weekly 2-h small-group (approximately 5
patients) self-management sessions given by a respiratory
nurse and a physiotherapist. The intention was to change
patient’s disease behaviour by increasing their knowledge,
confronting them with consequences of specific behaviour,
and helping patients acquire and practice skills to deal with
different components of their disease. Half of the patients,
distributed equally over the intervention and control group
(see Table 1), were educated in early recognition of exac-
erbations and were taught when to start a course of oral
prednisolone by using an action plan that was linked to
a daily diary. Methods and results of this intervention have
been described elsewhere.11 Four, 13, and 26 weeks after
the last session, the respiratory nurse contacted the
patients by phone with the goal to recall the items
addressed during the self-management sessions. Patients
were supplied with a booklet with the content of sessions
(regarding COPD; medication; nutrition & weight; exacer-
bations; exercise, relaxation & sputum mobilisation; and
communication).
COPE-active programme
For the development of the COPE-active programme the
most problematic activities of a sample of 15 COPD patients
were identified with help of the Canadian Occupational
Performance Measure12 and subsequently incorporated in
the programme: bicycling, walking, climbing stairs, and
lifting weights. Exact descriptions of the different training
activities and the used training schemes can be found in an
online supplementary file. Home exercises included:
walking or cycling, and strength exercises for the upper and
lower extremities.The 16 participating private physiotherapy practices
were situated in the catchment area of our hospital. All
physiotherapists had already attended a national COPD
course prior to the COPE-II study and were experienced in
caring for COPD patients. At start of this study, they had to
participate in an addition three-session course (11 h in
total) to refresh their knowledge about COPD in general and
to standardise the content of the COPE-active-programme.
In order to tailor the intensity of the programme to the
individual, we provided the physiotherapist with detailed
information about the individual patient at baseline: results
of the incremental maximal cycle ergometry test, incre-
mental shuttle walk test, lung function, and fat free mass.
The 11-month training period per patient was divided in
two parts: a ‘compulsory’ 6-month and a subsequent
optional but recommended 5-month period. Besides
improvement of physical condition in the first period and
preservation of these gains in the second period, behaviour
change towards exercise was strived for during the whole
period. Frequency of training sessions (first period: 3 times/
week; second period: 2 times/week) and intensity of the
exercises within the programme are in line with the latest
rehabilitation recommendations.13 During the 11-month
period, one training session per week was performed at
home (unsupervised) to facilitate behaviour change
towards exercise. Training was given in small groups (2e3
patients).
For the home-based sessions, a diary including training
information and illustrations of how to perform the exer-
cises was provided to increase the patient’s compliance
with the programme. Patients had to record whether they
had executed these exercises, their feelings during the
exercises, and their fatigue afterwards. Besides evaluation
of the appropriateness of the training intensity of the
different home-based exercises, physiotherapists went
through the diaries with the patients every week.
Outcome measures
The primary outcome was maximal exercise capacity
measured with the incremental shuttle walk test according
to the protocol of Singh et al.14 using a 10-min course.
Community based physiotherapeutic exercise in COPD 421A practice walk was performed before the baseline
measurement. The minimal important difference for indi-
vidual change is 47.5 m.15
Endurance capacity was measured with the endurance
shuttle walk test using a 10-min course16 and a walking
speed of 85% of the maximal incremental test walking
speed. HRQoL was measured with help of the self-admin-
istered Chronic Respiratory Questionnaire standardised
(CRQ-SAS).17 The minimal important difference for indi-
vidual change is 0.5/domain (dyspnoea, fatigue, emotional
functioning, mastery).18 Health status was evaluated by the
self-administrated Clinical COPD Questionnaire (CCQ).19 A
change of 0.4 represents the minimal important difference
at individual level.20 Anxiety and depression was measured
with the Hospital Anxiety and Depression Scale (HADS).21
This instrument produces separate scores for anxiety and
depression ranging from 0 to 21. A score over 10 is judged to
be a predictor of a clinical diagnosis of anxiety and
depression. Body composition was estimated using single-
frequency bioelectrical impedance analysis (Bodystat 1500,
Bodystat Ltd., Douglas, Isle of Man, UK). Fat free mass was
calculated from COPD- and gender specific regression
equations.22 Finally, daily activity was assessed by the
number of steps measured with the Yamax Digi-Walker SW-
200 (Tokyo, Japan) during 7-day periods at baseline, 7, and
12 months.
Statistical analyses
We calculated that 64 evaluable patients per treatment
group were required to detect a difference of 50 m (SD
100 m) on the incremental shuttle walk test between both
groups with 80% power and a two-sided 0.05 a-level test.
We used intention-to-treat principles for all analyses.
Between-group differences in continuous variables overFigure 1 Flow diagram of subject ptime were assessed by analysis of repeated measurements
(SPSS procedure for mixed models, version 12.0). Baseline
values were subtracted from follow-up values to correct for
baseline differences. Additional analyses were performed
using Chi-square statistics for categorical variables.
Results
Of the 421 eligible patients, 159 patients were assigned to
the intervention (n Z 80) or the control group (n Z 79)
(Fig. 1). Between the inclusion and the baseline measure-
ments three patients dropped out in each study group
(Fig. 1). Table 2 shows the baseline characteristics of the
remaining 153 patients.
The study groups were similar with respect to all
measured prognostic factors. Twenty-six patients took part
in the smoking cessation programme prior to the group
allocation. The self-reported quitting rate was 27% (nZ 7).
The “quitters” were equally distributed over the two study
groups (COPE-active: n Z 3; control group: n Z 4).
During the year after the baseline measurements, three
patients dropped out in the intervention group, as did eight
patients in the control group (see Fig. 1).
The three patients who dropped out of the intervention
group during the one-year follow-up all dropped out
directly after the baseline measurements before the start
of COPE-active. In addition seven patients assigned to the
intervention group refused to participate in the COPE-
active programme (transport problems (n Z 2); too busy
(n Z 3); disagreement with protocol (n Z 1); co-morbidity
(n Z 1)) but they completed the follow-up measurements.
So, 67 patients (87.0%) participated in the COPE-active
programme. After the first 6-month period, 11 patients
decided not to continue with COPE-active as was allowed
according to the protocol. Therefore, 56 patients (72.7%)rogress through the COPE II-study.
Table 2 Baseline characteristics of the two treatment groups.
Number of patients COPE-active n Z 77 Control n Z 76
Age (mean  SD; years) 62.9  8.1 63.9  7.8
Male (%) 58.4 57.9
Body mass index (mean  SD; kg/m2)a 26.1  5.0 26.8  4.4
Medical research council dyspnoea scale (mean  SD) 2.25  1.05 2.50  1.15
Smokers (%) 35 34
Lung function post bronchodilation (mean  SD)
FEV1 (L) 1.43  0.54 1.40  0.53
FEV1% predicted value 49.6  14.2 50.5  17.0
VC (L) 3.78  1.05 3.47  0.84
Inhaled corticosteroid use (%) 85.7 88.2
Incremental shuttle walk test (mean  SD; m)b 388  164.5 341  152.4
Endurance shuttle walk test (mean  SD; m)b 679  553.1 630  554.1
a Mean values were based on 77 and 75 patients in the COPE-active and control group respectively.
b Mean values were based on 77 and 74 patients in the COPE-active and control group respectively.
422 T. Effing et al.completed the whole 11-month training period. Twenty-five
patients (32.9%) in the control group received usual care
physiotherapy (non-standardised) during the 12-month
follow-up.
Results of the repeated measurements analysis of the
incremental shuttle walk test are presented in Fig. 2 and
Table 3. During the first 7 months of the follow-up period,
the intervention group showed a slight increase in walking
distance that remained stable until the end of the one-year
follow-up period. Conversely, the control group showed
a steady decline in walking distance over the whole follow-sisylanalocotorprep:tseTklaWelttuhSlatnemercnI
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Figure 2 Mean change (SE) from baseline in incremental
shuttle walk test walking distance (m) at 7 and 12 months after
baseline measurements of the COPE-active (:) and control
(-) group using an intention to treat analysis (number of
patients at baseline: COPE-active: 77; control: 74) and a per
protocol analysis (number of patients at baseline: COPE-active:
51; control: 74).up period. A significant between-group difference of 35.1 m
was found after 12 months (Table 3).
The probability of an improved walking distance by
47.5 m (the minimal important difference) or more after
one year was 1.91 times higher (95% CI 0.97e3.78) in the
intervention group compared to the control group. Simi-
larly, the probability of a decreased walking distance by
47.5 m or more after one year was 1.56 times higher (95% CI
0.92e2.70) in the control group compared to the inter-
vention group.
In addition, a per protocol analysis was performed, for
which 26 patients (34%) were omitted because of an
attendance of less than 70% of the physiotherapeutic
sessions (11-month period: <50 sessions; 6-month period:
<36 sessions). The major reasons for this lack of atten-
dance were not starting COPE-active (n Z 10) and new co-
morbidity (n Z 4). With this analysis a between-group
difference of 48.9 m was found (p < 0.01) (Fig. 2).
Results of the secondary outcomes are presented in
Table 3. The COPE-active group showed an improvement of
daily activity (steps/day) after 7 months that increased
further during the second period. Daily activity of the
control group decreased progressively. The mean between-
group difference over the whole period was 877 steps/day
(p Z 0.028), the between-group difference at 12 months
was even higher (1190 steps/day). An increase in the
endurance shuttle walk test in comparison with baseline
was seen at 7 and 12 months in the intervention group. The
walking distance of the control group diminished progres-
sively over the whole follow-up. A non-significant between-
group difference of 145.8 m was found after 12 months
(pZ 0.11). The CRQ dyspnoea-score was 0.33 points higher
in the COPE-active group compared to control (p Z 0.04).
No between-group differences were found in the other
CRQ-components and CCQ (sub)-scores, the HADS scores,
and percentage of fat free mass and no unexpected adverse
events occurred.
Discussion
This randomised controlled trial evaluated the effects of
a one-year community-based physiotherapeutic exercise
Table 3 Mean (SD) baseline scores, the mean differences (SE) from baseline at 7 months and 12 months after baseline, the between-group difference at 12 months, and the
overall mean difference between both study groups with the corresponding 95% confidence interval (95% CI).
Measuresa COPE-active Control
Difference with baselineb Difference with baselineb Treatment effect COPE-active - control
Baseline
mean (SD)
7 months
mean (SE)
12 months
mean (SE)
Baseline
mean (SD)
7 months
mean (SE)
12 months
mean (SE)
Δ 12
months
95% CI (Δ at
12 months)
Δ overallb 95% CI
(Δ overall)b
ISWT Nr of patients n Z 77 n Z 68 n Z 69 n Z 74 n Z 60 n Z 66
Distance (m) 387.7 (164.5) 12.2 (10.6) 11.1 (10.6) 341.4 (152.4) 12.1 (8.4) 24.0 (8.2) 35.1 8.4; 61.8 30.4 5.1; 55.7
ESWT Nr of patients n Z 77 n Z 68 n Z 68 n Z 74 n Z 60 n Z 66
Distance (m) 678.9 (553.1) 106.1 (67.4) 53.3 (67.4) 629.5 (554.1) 15.9 (55.6) 92.5 (54.5) 145.8 26.2; 317.8 134.5 29.0; 298.0
CRQ Nr of patients n Z 77 n Z 68 n Z 71 n Z 76 n Z 63 n Z 68
Dyspnoea 4.40 (1.44) 0.37 (0.13) 0.30 (0.13) 4.52 (1.38) 0.04 (0.12) 0.02 (0.12) 0.32 0.03; 0.67 0.33 0.01; 0.64
Fatique 4.55 (1.24) 0.15 (0.15) 0.15 (0.15) 4.13 (1.28) 0.03 (0.17) 0.06 (0.16) 0.09 0.34; 0.52 0.10 0.29; 0.50
Emotional
function
5.14 (1.19) 0.02 (0.11) 0.18 (0.11) 4.90 (1.02) 0.05 (0.12) 0.08 (0.12) 0.10 0.22; 0.42 0.07 0.21; 0.34
Mastery 5.35 (1.15) 0.13 (0.12) 0.33 (0.12) 5.30 (1.09) 0.14 (0.12) 0.22 (0.11) 0.11 0.21; 0.43 0.12 0.18; 0.41
CCQ Nr of patients n Z 77 n Z 67 n Z 70 n Z 74 n Z 60 n Z 66
Symptoms 2.35 (1.02) 0.06 (0.12) 0.11 (0.12) 2.92 (1.22) 0.06 (0.14) 0.17 (0.14) 0.06 0.30; 0.42 0.03 0.29; 0.34
Functional state 2.14 (1.17) 0.03 (0.12) 0.06 (0.12) 2.33 (1.29) 0.03 (0.12) 0.06 (0.12) 0.00 0.46; 0.22 0.03 0.34; 0.28
Mental state 0.93 (0.98) 0.06 (0.11) 0.14 (0.11) 1.03 (1.09) 0.08 (0.15) 0.12 (0.14) 0.02 0.37; 0.33 0.08 0.40; 0.23
Total 1.80 (0.89) 0.03 (0.08) 0.10 (0.08) 2.09 (0.95) 0.01 (0.10) 0.08 (0.10) 0.02 0.27; 0.23 0.03 0.26; 0.20
HADS Nr of patients n Z 76 n Z 67 n Z 69 n Z 76 n Z 62 n Z 68
Anxiety 4.26 (3.74) 0.17 (0.32) 0.66 (0.32) 5.38 (3.60) 0.28 (0.38) 0.61 (0.36) 0.05 1.00; 0.90 0.02 0.79; 0.84
Depression 3.96 (3.66) 0.37 (0.33) 0.71 (0.33) 5.24 (3.87) 0.48 (0.32) 0.30 (0.31) 0.41 1.31; 0.49 0.16 0.94; 0.62
Pedometer Nr of patients n Z 62 n Z 59 n Z 55 n Z 65 n Z 52 n Z 55
Steps (per day) 4472 (2715) 478.1 (348.5) 815.6 (358.6) 5224 (3464) 87.3 (313.6) 374.8 (306.4) 1190.4 255.6; 2125.2 876.6 95.4; 1657.7
FFM Nr of patients n Z 77 n Z 68 n Z 70 n Z 75 n Z 62 n Z 67
Fat free
mass (%)
34.7 (7.32) 1.1 (0.44) 0.8 (0.43) 35.2 (6.28) 0.1 (0.40) 0.2 (0.39) 0.6 0.55; 1.75 0.1 0.5; 0.6
a ISWT: incremental shuttle walk test; ESWT: endurance shuttle walk test; CRQ: chronic respiratory questionnaire; CCQ: clinical COPD
questionnaire; HADS: hospital anxiety and depression scale (HADS); FFM: percentage of fat free mass.
b Intention to treat analyses: results were obtained with repeated measurements analyses (SPSS), the “overall difference” is in contrast
with the “D 12 month” also influenced by the 7-month measurement.
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424 T. Effing et al.programme (COPE-active) incorporated in a self-manage-
ment programme compared to self-management alone. The
intervention group showed an improved maximal exercise
capacity and a positive change in daily activity, which was
used as a marker of behaviour change in comparison with
the control group.
The COPE-active group experienced a clear improvement
inmaximal exercise capacity compared to the steady decline
in the control group. A 35 m larger mean shift in the inter-
vention group than in the control group is rather impressive
as a group level effect, knowing that there will always be
patients who do not respond to exercise interventions.23 In
fact, patients in the intervention group were almost twice as
likely to improve their walking distance with a magnitude of
at least the recently publicised MID of 47.5 m.15
In contrast tomany other studies (e.g., Ref.24e27), we used
an ‘intention to treat’ e principle for our primary analyses,
meaning that all patients who were assigned to the inter-
vention group at baseline were included in the analysis. As
expected, applyingaper protocol analysis (withpotential bias
due to incomparable groups28) led in our study to a larger
between-groupdifference in favourof the interventiongroup.
The study population comprised relatively severe COPD
patients with a median one-year exacerbation rate of 3 in
both study groups. This relatively high exacerbation rate
might explain the deterioration in exercise capacity in the
control group and also the relatively small increase of
exercise capacity in the intervention group because exac-
erbations do not only lead to a reduced walking distance
during an exacerbation, but walking distance remains
reduced also after the exacerbation.29
Besides the changes in exercise capacity, we intended to
change behaviour with regard to exercise with our relatively
long lasting programme.30 The fact that only 11 of the 67
patients who started the training decided not to continue
after the first 6-month training period seems to indicate at
least ahighmotivation to continueexercising under guidance
of the physiotherapist. Moreover, we found a between-group
difference (1190 steps/day) in daily activity in favour of the
intervention group. Baseline scores of patients in the COPE-
active and control group were 4472 and 5224 steps/day
respectively, which places the difference of almost 1200
steps in more perspective, i.e., an improvement of approx-
imately 25%. We believe that these results indicate behav-
ioural change with regard to levels of daily activity.
A positive trend, though not significant, was seen in
endurance capacity. The change in endurance exercise
capacity showed the same trend as the change in maximal
(incremental) exercise capacity, but the substantial
between-group difference at 12 months of 145.8 m did not
reach significance. The latter is explainedby a large standard
deviation, andby a ceiling effect (i.e., 12 COPE-active and 14
controls already walked the maximum 20 min at baseline).
A statistically significant between-group difference of
the CRQ-dyspnoea domain was found over the 12-month
period. This is in line with our expectations, because
desensitisation to dyspnoea seems to be an important
mechanism in improving the exercise tolerance of COPD.7
Because no significant nor clinically relevant effects were
detected in the other CRQ-domains, we can conclude that
our HRQoL-results do not match results from the litera-
ture.31 Lack of power and relatively high CRQ-baselinescores are possible explanations. Finally, no changes in
anxiety and depression were found, but average baseline
scores were so low that expecting a further decrease might
not be reasonable.
In literature scant information is available about the
effects of community-based physiotherapeutic reactivation
programs in general,8,9 and even less about their effect on
daily activity. These programmes have a great accessibility
and could therefore be an excess value for the COPD
community in addition to in-hospital and home-based
rehabilitation programmes that are already proven effec-
tive.5,7 We have demonstrated effects of such a programme
on exercise capacity and daily activity. But, before
a decent decision about implementation can be made,
cost-effectiveness data need to be evaluated to properly
balance the effects and costs against each other, which we
will do in an additional paper.
Probably larger effects of this intervention can be
expected in a more exercise naive population for several
reasons. First, our included patients were not “fresh”
patients. The majority of the patients was under supervi-
sion of our chest physicians for years already. Therefore,
aspects as e.g., the importance of exercising were brought
to their attention many times before. Also, we designed our
study to evaluate whether the positive effects of a pro-
active and mandatory training programme would surpass
the effects of variable and less strict exercise programmes
in usual care. Hence, patients were allowed to receive
physiotherapy at the time of inclusion and control patients
were allowed to receive physiotherapy during the study as
part of their usual care. Between-group effect might have
been diminished by the latter and by the fact that for
intervention patients with previous experience in physio-
therapy, the programme might only have acted as a main-
tenance programme with limited effects as a result. Finally,
all patients received self-management instructions on
exercising as part of the life style advices. This might also
have slightly diminished the room for improvement in the
active arm compared to the control arm, even though the
effects of self-management in this sense have not been
found to be very large.4
Using a two-by-two factorial design confers the theo-
retical risk of interaction between both interventions.
Since the proportion of patients receiving physiotherapy
was the same in both study groups, possible (additional)
effects of the COPE-active programme will have affected
both study groups and will thereby not directly influence
the between-group differences. Before the final analysis we
have checked for interaction between both interventions
and we concluded that interaction was not present.
We conclude that a community-based reactivation pro-
gramme is valuable in patients with moderate to severe
COPD and improves exercise capacity. Even more impor-
tant, the programme improves actual daily activities after
one-year which indicates behaviour change with regard to
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